UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12

• Published in: British journal of ophthalmology Vol. 99; no. 8; pp. 1045 - 1050
• Main Authors: Lee, Aaron Y, Lee, Cecilia S, Butt, Thomas, Xing, Wen, Johnston, Robert L, Chakravarthy, Usha, Egan, Catherine, Akerele, Toks, McKibbin, Martin, Downey, Louise, Natha, Salim, Bailey, Clare, Khan, Rehna, Antcliff, Richard, Varma, Atul, Kumar, Vineeth, Tsaloumas, Marie, Mandal, Kaveri, Liew, Gerald, Keane, Pearse A, Sim, Dawn, Bunce, Catey, Tufail, Adnan
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.08.2015
• Subjects: Age; Aged; Aged, 80 and over; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Clinical medicine; Data collection; Databases, Factual; Datasets; Diabetic retinopathy; Electronic Health Records - statistics & numerical data; Female; Hospitals; Humans; Intravitreal Injections; Macular degeneration; Male; Medical records; Methods; Middle Aged; Patients; Ranibizumab; Retreatment; Studies; Surveillance; United Kingdom; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology; Wet Macular Degeneration - diagnosis; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - physiopathology; United Kingdom > UK; Drugs; Macula; Retina; Treatment Medical

Background/aimsTo study the effectiveness and clinical relevance of eyes treated with good (better than 6/12 or >70 Early Treatment Diabetic Retinopathy Study letters) visual acuity (VA) when initiating treatment with ranibizumab for neovascular age-related macular degeneration (nAMD) in the UK N...